Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ0S5C)

Drug Name

N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile Drug Info

Synonyms

dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Cathepsin K (CTSK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Odanacatib	DM1EO3G	Osteoporosis	FB83.0	Phase 3	[2]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VEL-0230	DMDSC63	Rheumatoid arthritis	FA20	Phase 1	[4]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[5]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[5]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[5]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[6]
PMID27998201-Compound-15	DMOB8LU	Pain	MG30-MG3Z	Patented	[5]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1	DM1SH5R	Pain	MG30-MG3Z	Patented	[5]
PMID27998201-Compound-8	DMZK0SY	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin L (CTSL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KGP94	DM2NZ6K	Coagulation defect	3B10.0	Clinical trial	[7]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[5]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[5]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[5]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[6]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[5]
Phenylalanine derivative 1	DMVYP8K	Glioma	2A00.0	Patented	[5]
PMID27998201-Compound-7	DMU4QYR	Abdominal aortic aneurysm	BD50.4	Patented	[5]
PMID27998201-Compound-6	DM0LGTY	N. A.	N. A.	Patented	[5]
PMID27998201-Compound-1	DM5QH4C	Coronavirus infection	1D92	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cathepsin S (CTSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7625	DMDGPKS	Autoimmune disease	4A40-4A45	Phase 2	[8]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[3]
VBY- 891	DMTKPH4	Autoimmune diabetes	5A10	Phase 1	[9]
VBY- 036	DMULRYC	Neuropathic pain	8E43.0	Phase 1	[10]
VBY-129	DM4YIWK	Autoimmune diabetes	5A10	Phase 1	[11]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[5]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[5]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[5]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[6]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin K (CTSK)	TTDZN01	CATK_HUMAN	Inhibitor	[1]
Cathepsin L (CTSL)	TT36ETB	CATL1_HUMAN	Inhibitor	[1]
Cathepsin S (CTSS)	TTUMQVO	CATS_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707.
2	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
4	Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
5	Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
6	An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
7	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
10	Clinical pipeline report, company report or official report of ViroBay.
11	Clinical pipeline report, company report or official report of ViroBay.